Charles Schwab Investment Management Inc. Sells 5,210 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Charles Schwab Investment Management Inc. lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.7% in the third quarter, HoldingsChannel.com reports. The firm owned 747,291 shares of the company’s stock after selling 5,210 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $86,103,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $28,000. Innealta Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth $30,000. New Covenant Trust Company N.A. acquired a new stake in shares of Neurocrine Biosciences during the 1st quarter worth $32,000. EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences in the second quarter worth $35,000. Finally, Blue Trust Inc. raised its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $126.59 on Thursday. Neurocrine Biosciences, Inc. has a 52-week low of $110.81 and a 52-week high of $157.98. The company’s 50 day moving average price is $118.97 and its 200-day moving average price is $131.71. The company has a market capitalization of $12.82 billion, a P/E ratio of 33.94 and a beta of 0.35.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 1st. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Oppenheimer lifted their price target on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Robert W. Baird upped their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.